Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89

Benzinga · 2d ago
Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.